Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

Leukemia Research

Highlights

 

  • We validate Sokal, Euro, and EUTOS scores on 220 Chinese CP-CML patients.
  • EUTOS score could stratify CP-CML patients into 2 risk groups in OS and PFS significantly.
  • EUTOS score could distribute CP-CML patients into 2 risk groups in cumulative incidence of CCyR significantly by Fine and Gray model.
  • EUTOS score could predict the duration of first CCyR.
  • Low EUTOS index predicted for the achievement of CCyR.

Abstract

Sokal, Euro and newly developed EUTOS scoring systems were validated in 220 Chinese chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib. In the EUTOS low-risk and high-risk groups, the 5-year OS was 98.7% vs. 71.4% (P < 0.0001), and the 5-year cumulative incidence of complete cytogenetic response (CCyR) was 92.4% vs. 53.8% (P < 0.0001). EUTOS score also predicted progression-free survival and duration of CCyR. Low EUTOS index predicted for CCyR. However, Sokal and Euro scores mainly could not discriminate the intermediate-risk from high-risk group in either survival or CCyR. EUTOS score forecasts the prognosis of CP-CML patients treated with first-line imatinib.

Abbreviation: EUTOS - European Treatment and Outcome Study.

Keywords: EUTOS, Chronic myeloid leukemia, Complete cytogenetic response, Overall survival, Progression-free survival, Prognosis.

Footnotes

a Department of Clinical Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, People's Republic of China

b Department of Hemopathology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, People's Republic of China

c State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, People's Republic of China

lowast Corresponding author at: Department of Clinical Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, People's Republic of China. Tel.: +86 22 23909280; fax: +86 22 27232515.